Swiss National Bank Boosts Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX)

Swiss National Bank increased its position in Tango Therapeutics, Inc. (NASDAQ:TNGX) by 13.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 94,900 shares of the company’s stock after purchasing an additional 11,000 shares during the quarter. Swiss National Bank’s holdings in Tango Therapeutics were worth $293,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in TNGX. State Street Corp lifted its holdings in Tango Therapeutics by 26.8% in the 3rd quarter. State Street Corp now owns 2,318,208 shares of the company’s stock worth $17,850,000 after buying an additional 489,949 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Tango Therapeutics by 11.6% during the third quarter. Geode Capital Management LLC now owns 1,368,262 shares of the company’s stock worth $10,538,000 after acquiring an additional 142,710 shares during the last quarter. Barclays PLC lifted its stake in shares of Tango Therapeutics by 78.3% in the third quarter. Barclays PLC now owns 126,281 shares of the company’s stock worth $972,000 after acquiring an additional 55,470 shares in the last quarter. Los Angeles Capital Management LLC purchased a new position in Tango Therapeutics in the fourth quarter valued at about $218,000. Finally, Verition Fund Management LLC acquired a new stake in Tango Therapeutics during the 3rd quarter valued at approximately $247,000. 78.99% of the stock is owned by institutional investors and hedge funds.

Tango Therapeutics Stock Performance

Shares of TNGX stock opened at $1.47 on Monday. The stock has a market capitalization of $158.92 million, a price-to-earnings ratio of -1.25 and a beta of 0.87. Tango Therapeutics, Inc. has a one year low of $1.43 and a one year high of $12.02. The company’s 50-day simple moving average is $2.37 and its 200-day simple moving average is $4.02.

Tango Therapeutics (NASDAQ:TNGX) last released its earnings results on Thursday, February 27th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%. The firm had revenue of $4.12 million for the quarter, compared to the consensus estimate of $7.84 million. As a group, research analysts forecast that Tango Therapeutics, Inc. will post -1.19 EPS for the current year.

Insider Buying and Selling

In other Tango Therapeutics news, CEO Barbara Weber sold 9,778 shares of the stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total transaction of $29,236.22. Following the sale, the chief executive officer now directly owns 1,631,264 shares of the company’s stock, valued at approximately $4,877,479.36. This represents a 0.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 24,268 shares of company stock worth $72,561 over the last ninety days. 6.30% of the stock is owned by insiders.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Tango Therapeutics in a report on Thursday, December 5th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tango Therapeutics has a consensus rating of “Buy” and an average target price of $12.33.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.